CombiGene

6,96SEK +3,11 %
Vær den første som følger denne virksomhed

CombiGene is a gene therapy company that focuses on developing new treatments intended for diseases related to the central nervous system and metabolic diseases. The company focuses on drug-resistant focal epilepsy and partial lipodystrophy, respectively. CombiGene collaborates with several actors in both academia and industry. The company is headquartered in Lidingö.

Omsætning
26,7 mio.
EBIT %
-26,03 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
COMBI
Daglig lav / høj pris
6,62 / 7 SEK
Markedsværdi
137,82 mio. SEK
Aktieomsætning
80,87 t SEK
Volumen
12 t

Finanskalender

New issue of Ingeneious!

Pressemeddelelse24.05.2023
New issue of Ingeneious!

Pressemeddelelse12.01.2023